Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
JAMA. 2003.
PMID: 12783912
Clinical Trial.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1999 | 35 |
| 2000 | 57 |
| 2001 | 163 |
| 2002 | 213 |
| 2003 | 197 |
| 2004 | 315 |
| 2005 | 380 |
| 2006 | 279 |
| 2007 | 175 |
| 2008 | 99 |
| 2009 | 79 |
| 2010 | 65 |
| 2011 | 49 |
| 2012 | 42 |
| 2013 | 38 |
| 2014 | 23 |
| 2015 | 32 |
| 2016 | 22 |
| 2017 | 37 |
| 2018 | 28 |
| 2019 | 18 |
| 2020 | 16 |
| 2021 | 21 |
| 2022 | 15 |
| 2023 | 15 |
| 2024 | 13 |
| 2025 | 17 |
| 2026 | 2 |
Search Results
2,318 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
COX-1 and COX-2 inhibitors.
Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):801-20. doi: 10.1053/bega.2001.0236.
Best Pract Res Clin Gastroenterol. 2001.
PMID: 11566042
Review.
Truly selective COX-2 inhibitors have been shown to have no effect on gastric mucosal prostaglandin synthesis, to cause no acute injury, and no chronic ulceration compared to placebo. ...The VIGOR study has raised the possibility that some NSAIDs, particularly na …
Truly selective COX-2 inhibitors have been shown to have no effect on gastric mucosal prostaglandin synthesis, to cause no acute inju …
Rofecoxib.
Drugs. 1999 Sep;58(3):499-505; discussion 506-7. doi: 10.2165/00003495-199958030-00016.
Drugs. 1999.
PMID: 10493277
Review.
Rofecoxib selectively inhibits cyclo-oxygenase-2 in a dose-dependent manner in humans. No significant inhibition of cyclo-oxygenase-1 is observed with rofecoxib up to doses of 1000 mg. ...Rofecoxib is also an effective analgesic in patients with primar …
Rofecoxib selectively inhibits cyclo-oxygenase-2 in a dose-dependent manner in humans. No significant inhibition of cyclo-oxygenase-1 …
Rofecoxib.
Expert Opin Pharmacother. 2000 Jul;1(5):1053-66. doi: 10.1517/14656566.1.5.1053.
Expert Opin Pharmacother. 2000.
PMID: 11249495
Review.
Rofecoxib (Vioxx, Merck & Co., Inc.) is a new orally-effective non-steroidal anti-inflammatory drug (NSAID) approved for treatment of acute pain, fever, primary dysmenorrhea and pain and inflammation in osteoarthritis (OA). ...As cells in the gastrointestinal (G …
Rofecoxib (Vioxx, Merck & Co., Inc.) is a new orally-effective non-steroidal anti-inflammatory drug (NSAID) approved for t …
Rofecoxib for osteoarthritis.
Cochrane Database Syst Rev. 2005 Jan 25;2005(1):CD005115. doi: 10.1002/14651858.CD005115.
Cochrane Database Syst Rev. 2005.
PMID: 15654705
Free PMC article.
Comparable trials were pooled using fixed effects model. MAIN RESULTS: Twenty-six RCTs were included. The comparators were placebo, diclofenac, ibuprofen, naproxen, nimesulide, nabumetone, paracetamol, celecoxib and Arthrotec. The evidence reviewed indicated …
Comparable trials were pooled using fixed effects model. MAIN RESULTS: Twenty-six RCTs were included. The comparators were placebo …
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
JAMA. 2003 Jun 4;289(21):2819-26. doi: 10.1001/jama.289.21.2819.
JAMA. 2003.
PMID: 12783912
Clinical Trial.
CONTEXT: Laboratory evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer disease (AD), along with epidemiological evidence, suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) may favorably influence the course of the disease …
CONTEXT: Laboratory evidence that inflammatory mechanisms contribute to neuronal injury in Alzheimer disease (AD), along with …
Cyclooxygenase-2 inhibitors.
Curr Opin Gastroenterol. 2005 Nov;21(6):660-4. doi: 10.1097/01.mog.0000182860.11669.04.
Curr Opin Gastroenterol. 2005.
PMID: 16220041
Review.
Some, but not all, studies have suggested increased myocardial infarction with certain cyclooxygenase-2 inhibitors, in particular rofecoxib. It is unclear whether this is a class effect because there are inconclusive data to incriminate celecoxib despite a relativel …
Some, but not all, studies have suggested increased myocardial infarction with certain cyclooxygenase-2 inhibitors, in particular rofecox …
Rofecoxib in migraine.
Expert Rev Neurother. 2005 Jan;5(1):55-61. doi: 10.1586/14737175.5.1.55.
Expert Rev Neurother. 2005.
PMID: 15853474
Review.
Among the available drugs, nonsteroidal anti-inflammatory drugs still represent effective options and a new class of nonsteroidal anti-inflammatory drugs known as selective cyclooxygenase-2 inhibitors may represent an even better-tolerated therapy with regard to gastrointe …
Among the available drugs, nonsteroidal anti-inflammatory drugs still represent effective options and a new class of nonsteroidal ant …
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Cochrane Database Syst Rev. 2020 Apr 30;4(4):CD011459. doi: 10.1002/14651858.CD011459.pub2.
Cochrane Database Syst Rev. 2020.
PMID: 32352165
Free PMC article.
One trial (2528 participants) investigated the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib (200 mg twice daily) and the non-selective NSAID naproxen (220 mg twice daily) for preventing dementia in cognitively healthy older adults with a family history of Alzheimer …
One trial (2528 participants) investigated the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib (200 mg twice daily) and the non-selective NSAI …
The safety of rofecoxib.
Expert Opin Drug Saf. 2005 May;4(3):491-9. doi: 10.1517/14740338.4.3.491.
Expert Opin Drug Saf. 2005.
PMID: 15934855
Review.
Recently, new evidence have become available indicating that rofecoxib indeed increases the number of thrombo-embolic events. These data have resulted in the complete withdrawal of rofecoxib from the market. Was it scientifically reasonable to withdraw rofecoxib …
Recently, new evidence have become available indicating that rofecoxib indeed increases the number of thrombo-embolic events. These d …
COX-2 inhibitors.
Med J Aust. 2000 Oct 16;173(8):433-6.
Med J Aust. 2000.
PMID: 11090038
Two COX-2 inhibitors are currently available in Australia--celecoxib, which is taken twice daily, and rofecoxib, which is taken once daily. Both drugs act rapidly in providing pain relief and their anti-inflammatory analgesic effect in osteoarthritis and rheumatoid …
Two COX-2 inhibitors are currently available in Australia--celecoxib, which is taken twice daily, and rofecoxib, which is taken once …
Cite